About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Dana-Farber Cancer Institute
https://www.dana-farber.org/
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
ASCO® 2023 Summary: "Prostate Cancer Updates From The Recent Trials"
By
Dana-Farber Cancer Institute
FEATURING
Jacob Berchuck
,
Mary-Ellen Taplin
By
Dana-Farber Cancer Institute
FEATURING
Jacob Berchuck
,
Mary-Ellen Taplin
178 views
July 21, 2023
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
ASCO® 2023
22:44
Dana-Farber Cancer Institute
ASCO® 2023 Summary: "RCC Updates From The Recent Trials"
Feat.
W. Xu,
T. Choueiri
20:05
Dana-Farber Cancer Institute
ASCO® 2023 Summary: "Prostate Cancer Updates From The Recent Tr…
Feat.
J. Berchuck,
M. Taplin
18:57
Dana-Farber Cancer Institute
ASCO® 2023 Summary: "Bladder Cancer Updates From The Recent Tri…
Feat.
C. Mantia,
J. Bellmunt
23:16
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients…
Feat.
B. McGregor
12:04
Insights from 2023 ASCO® Annual Meeting
INSIGHT Study - Ripretinib vs. Sunitinib in Patients With Advanced G…
Feat.
S. George
06:11
ecancer
ASCO® 2023 Insights: "Key Head & Neck Data"
Feat.
G. Hanna
01:25
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "INDIGO Trial on Vorasidenib vs. Placebo i…
Feat.
P. Wen
01:41
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "Dose Expansion Results of the Bifunctiona…
Feat.
G. Hanna
02:27
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "Initial Chemo for Locally Advanced & …
Feat.
J. Luo
01:51
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "Effect of a Telephone-Based Weight Loss I…
Feat.
J. Ligibel
02:25
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "Prognosis & Trends in Adjuvant Chemo …
Feat.
P. Tarantino
01:46
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "TROPiCS-02 Final OS Analysis of Sacituzum…
Feat.
S. Tolaney
05:00
ecancer
ASCO® 2023 Insights: "Phase 3 CONTACT-03 Study - Efficacy &…
Feat.
T. Choueiri
02:12
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "CONTACT-03 Study: Efficacy and Safety of …
Feat.
T. Choueiri
02:32
Dana-Farber Cancer Institute
ASCO® 2023 Insights: "Prognostic Impact of PSA Nadir (n)≥0.1ng/…
Feat.
P. Ravi
07:12
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Association of Host Immune Signatures Wit…
Feat.
E. Saad
09:44
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Long-Term Safety of Avelumab 1L Maintenan…
Feat.
J. Bellmunt
09:12
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Cabozantinib, Nivolumab, and Ipilimumab f…
Feat.
B. McGregor
